Goldman Sachs Reiterates Neutral Rating on Tarsus Pharmaceuticals (TARS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: TARS) | Delayed: 69.07 -3.57 (4.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $72.64 | 52 Week High | $ | |||
| Open | $74.01 | 52 Week Low | $ | |||
| Day High | $74.63 | P/E | N/A | |||
| Day Low | $65.34 | EPS | $ | |||
| Volume | 2,550,726 | |||||
